OncoMatch

OncoMatch/Clinical Trials/NCT06184009

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

Is NCT06184009 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ALL, High risk for pediatric acute lymphoblastic leukemia.

Phase 2RecruitingJae Wook LeeNCT06184009Data as of May 2026

Treatment: ALL, High risk — * Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \&lt; 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation <!-- --> 1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification 1. BM MRD \&lt; 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen * Difference in the number of \&#39;interim maintenance(IM)\&#39; and \&#39;delayed intensification(DI)\&#39; is important for chemotherapies based on MRD.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: KMT2A (MLL) rearrangement

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: steroid

Exception: as specified in the above selection criteria

Patients who have already received steroid treatment for newly diagnosed ALL specified in the above selection criteria

Cannot have received: chemotherapy (intrathecal cytarabine)

Exception: more than one dose

chemotherapies more than one intrathecal cytarabine treatment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify